PMC:7536913 / 8971-9186 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":173,"end":178},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":173,"end":178},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T26","span":{"begin":51,"end":59},"obj":"Disease"},{"id":"T27","span":{"begin":173,"end":186},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T45","span":{"begin":173,"end":178},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T46","span":{"begin":173,"end":178},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T47","span":{"begin":173,"end":178},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T48","span":{"begin":173,"end":178},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}

{"project":"LitCovid-PubTator","denotations":[{"id":"79","span":{"begin":60,"end":68},"obj":"Species"},{"id":"80","span":{"begin":111,"end":119},"obj":"Species"},{"id":"83","span":{"begin":51,"end":59},"obj":"Disease"},{"id":"84","span":{"begin":173,"end":186},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"Tax:9606"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"Tax:9606"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:D006333"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":139,"end":160},"obj":"Phenotype"},{"id":"T4","span":{"begin":173,"end":186},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001635"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}

{"project":"LitCovid-sentences","denotations":[{"id":"T61","span":{"begin":0,"end":215},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Similar to how we take such exceptional action for COVID‐19 patients, we need to advance regulatory policy for patients with life‐limiting autoimmune conditions, late‐stage heart failure, or other serious illnesses."}